PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
124.50M
Better than AFMD's estimated revenue of 13.28M.
-24.90M
Worse than AFMD's estimated ebitda of -13.28M.
0.56
Better than AFMD's estimated eps of -0.96.
16.74M
Better than AFMD's estimated net income of -14.32M.
-24.90M
Worse than AFMD's estimated ebit of -13.28M.
4.61B
Worse than AFMD's estimated sg&a expense of 14.13M.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than AFMD's revenue growth rate of -0.66%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than AFMD's ebitda margin of -100.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Better than AFMD's ebit margin of -100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to AFMD's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than AFMD's receivables as percentage of revenue of 19.67%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than AFMD's inventories as percentage of revenue of 2.08%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than AFMD's payables as percentage of revenue of 56.59%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than AFMD's capex as percentage of revenue of -12.95%.
4.99%
Better than AFMD's weighted average cost of capital (wacc) of 10.05%.
5.02%
Better than AFMD's cost of equity of 13.84%.
4.08%
Better than AFMD's cost of debt of 9.33%.
-0.23
Better than AFMD's beta of 2.07.
30.07M
Worse than AFMD's diluted shares outstanding of 14.94M.
1.57M
Better than AFMD's total debt of 21.90M.
49.31M
Better than AFMD's total equity of 4.17M.
50.89M
Better than AFMD's total capital of 26.07M.
3.09%
Better than AFMD's debt weighting of 84.01%.
96.91%
Better than AFMD's equity weighting of 15.99%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to AFMD's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than AFMD's net debt of -21.71M.
71.33M
Better than AFMD's equity value of -100.35M.
2.37
Better than AFMD's equity value per share of -6.72.